PLA2G7
Platelet-activating factor acetylhydrolase
Protein Summary
Modulates the action of platelet-activating factor (PAF) by hydrolyzing the sn-2 ester bond to yield the biologically inactive lyso-PAF. Has a specificity for substrates with a short residue at the sn-2 position. It is inactive against long-chain phospholipids. The protein encoded by this gene is a secreted enzyme that catalyzes the degradation of platelet-activating factor to biologically inactive products. Defects in this gene are a cause of platelet-activating factor acetylhydrolase deficiency. Two transcript variants encoding the same protein have been found for this gene.[provided by RefSeq, Dec 2009]
- ENST00000274793
- ENSP00000274793
- ENSG00000146070
- ENST00000537365
- ENSP00000445666
- PAFAH
- PAFAD
- PAFAH
- LP-PLA2
- LDL-PLA2
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
PubMedID | 0.95 | ||
biological term | 0.94 | ||
kinase perturbation | 0.84 | ||
gene perturbation | 0.77 | ||
transcription factor perturbation | 0.74 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 629.42 (req: < 5)
Gene RIFs: 284 (req: <= 3)
Antibodies: 334 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 629.42 (req: >= 5)
Gene RIFs: 284 (req: > 3)
Antibodies: 334 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 11
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 354
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 1